RxDoctor Payments DataLook up a doctor →

Jaafer Golzar, MD

Interventional Cardiology · Oak Lawn, ILNPI 1073577193

Payments from drug & device makers

$258,197in general payments, 2019–2025

Across 613 payments — averaging $421.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$61K
  • M.a. Med Alliance S.A.$46K
  • Angiodynamics, Inc.$43K
  • Penumbra, Inc.$31K
  • Endologix LLC$29K
  • Johnson & Johnson$18K
  • plus $30K from 31 others
$2,775in research payments, 2019–2025

Across 2 payments — averaging $1387.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$3K

What the payments were for

  • Consulting fees$86,11057%
  • Speaking & faculty fees$25,33717%
  • Travel & lodging$16,53811%
  • Food & beverage$23,34815%
  • Education$1980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,197 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$113,633
Medicare patients
492
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$87,373
XareltoRivaroxaban81$71,896
NexlizetBempedoic Acid/Ezetimibe99$60,563
Repatha SureclickEvolocumab84$58,224
EliquisApixaban59$48,307
EntrestoSacubitril/Valsartan26$27,810
Repatha SyringeEvolocumab27$11,714
JardianceEmpagliflozin11$8,272
Rosuvastatin Calcium214$3,308
ClopidogrelClopidogrel Bisulfate295$2,661
Ranolazine ErRanolazine15$1,408
Cilostazol48$1,376
Metoprolol Succinate93$1,144
Nifedipine ErNifedipine39$1,026
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide58$778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$640$87,37382 claims
Johnson & JohnsonXarelto$17,998$71,89681 claims
Esperion Therapeutics, Inc.Nexlizet$352$60,56399 claims
PfizerEliquis$35$48,30759 claims
NovartisEntresto$216$27,81026 claims
Boehringer IngelheimJardiance$178$8,27211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →